T. Rowe Price Associates’s Enfusion, Inc. ENFN Stock Holding History

T. Rowe Price Associates’s Portfolio ENFN Stock Details ENFN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,916	Closed	-$245K	–	3171
2025 Q1	$245K	Buy	21,916 +2,170	+11%	+$24K	﹤0.01%	2550
2024 Q4	$204K	Buy	19,746 +3,238	+20%	+$31.3K	﹤0.01%	2674
2024 Q3	$157K	Buy	16,508 +1,051	+7%	+$9.07K	﹤0.01%	2734
2024 Q2	$132K	Buy	15,457 +4,444	+40%	+$40.7K	﹤0.01%	2701
2024 Q1	$102K	Buy	+11,013	New	+$96.9K	﹤0.01%	2783

Other funds holding ENFN

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

T. Rowe Price Associates's ENFN Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Enfusion, Inc. (ENFN) in Q2 2025, closing a stake of 21,916 shares — an estimated $245K sold.

T. Rowe Price Associates first reported a position in ENFN in Q1 2024 and held it in 5 quarters. The position peaked at $245K in Q1 2025. 2 funds tracked by Wall St. Rank hold ENFN as of Q2 2025.

T. Rowe Price Associates reported no remaining Enfusion, Inc. position as of Q2 2025 after selling out during the quarter.
T. Rowe Price Associates sold 21,916 Enfusion, Inc. shares in Q2 2025, an estimated $245K.
T. Rowe Price Associates first reported a position in Enfusion, Inc. in Q1 2024 and held it in 5 quarters.
T. Rowe Price Associates's Enfusion, Inc. position peaked at $245K in Q1 2025.
2 funds tracked by Wall St. Rank held Enfusion, Inc. as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.